PubMed Health⌕ Search

Biomedical subjects

G F Jensen

Publications and source records attributed to G F Jensen.

29 records · Page 2Linked to original sources
PubMed1982

Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium.

A controlled therapeutic trial on seventy-four 70-year-old women was carried out with the purpose of finding the optimal treatment for post menopausal osteoporosis. The bone mineral content (BMC) was measured by I-photonabsorptiometry at two sites in the distal part of the forearms, where the trabecular/cortical ratio is 0.25 and 1.5, respectively. Radiographs were done on the right hand to measure the metacarpal bone mass (cortical area/total area=CA/TA. After observing the spontaneous course of bone loss for 6 months the participants were allocated at random to 12 months' treatment with 1,25-dihydroxycholecalciferol [1,25(OH)2D3] and oestrogen/gestagen, alone or in combination, and calcium. The groups treated with oestrogen/gestagen [with or without 1,25(OH)2D3] showed a highly significant increase in BMC. In contrast bone mineral remained unchanged or decreased in both the calcium and the 1,25(OH)2D3 groups with a tendency towards more pronounced negative bone balance in the 1,25-(OH)2D3 group. Seven out of nineteen patients of 1,25(OH)2D3 developed hypercalcaemia, which necessitated a reduction in dosage. It is concluded that the new vitamin D metabolite, 1,25(OH)2D3, given in clinically acceptable doses, is without value in the treatment of post menopausal osteoporosis.

Aged↗
PubMed1982

1,25(OH)2D3 and renal function. A controlled clinical study in normal elderly women.

A controlled study of the effect of 1,25(OH)2D3 was performed in 58 normal 70-year-old Danish women. After 6 months; observation of the spontaneous course the participants were randomized to treatment with either 1,25(OH)2D3 (0.5 micrograms daily) or placebo. Both groups received 500 mg calcium daily. Seven out of 20 participants treated with 1,25(OH)2D3 developed slight hypercalcaemia which disappeared after dose adjustment. One participant in the placebo group developed slight hypercalcaemia. A highly significant increase in serum creatinine was observed in the 1,25(OH)2D3 group when compared with the initial value and with the change in the placebo group. Serum creatinine remained elevated throughout the study despite normalization of serum calcium. It is concluded that 1,25(OH)2D3 treatment in normal, elderly women has a negative effect on the renal function as estimated from serum creatinine.

Aged↗
PubMed1982

Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis.

The incidence of spontaneous postmenopausal fractures and their relationship to menopausal age and bone mass were determined in a representative sample of 70-year-old Danish women. Two hundred and eighty-five women (1.2% of all women in that age group) were examined by case history, by 125I photon absorptiometry in both forearms (BMC), by metacarpal index (CA/TA), and by lateral radiographs of the spine. Twenty-four per cent of the participants had sustained single fractures, and 20% multiple fractures. Nineteen per cent had fractures of the lower forearm, 5% of the proximal humerus, 4% of the hip, and 5% crush fractures of the spine. These comprise Group I fractures, the most definite expressions of osteoporosis. The remaining other long bone fractures (7%) and spinal wedge fractures (18%) comprise Group II fractures. Group I cases were characterized by an earlier onset of the menopause and a definite decrease in bone mass, as judged from BMC and CA/TA, as compared with the nonfracture group. Group II cases did not display this distinction. Of Group I cases, those with multifractures differed from those with single fractures by having a five-year earlier occurrence of first fracture, a further decrease in bone mass, and a slightly raised serum alkaline phosphatase level. Serum calcium and phosphate levels were the same in all groups.

Age Factors↗
PubMed1982

Fracture frequency and bone preservation in postmenopausal women treated with estrogen.

Two hundred eighty-five normal 70-year-old Danish women were divided according to postmenopausal use of gonadal hormones into 3 groups: 1 virtually untreated (3 months or less, N = 231), 1 treated over a short term (4 months to 6 years, N = 36), and 1 treated over a long term (6 years or more, N = 18). The 3 groups had been treated for a median of 0, 6, and 70%, respectively, of their postmenopausal years. The degree of bone loss varied inversely with the duration of postmenopausal hormone treatment. Bone mineral content was 11.8% higher in the long-term treated group than in the untreated group (P less than .05). Likewise, the metacarpal bone mass was 8.5% greater (P less than .01). The number of women with postmenopausal fractures was 13% lower in the long-term treated group than in the untreated group (Difference not significant). Data from this retrospective study present evidence that estrogen protects bones in elderly women.

Aged↗
PubMed1980

Very-low-calorie diet in the treatment of massive obesity: preliminary experience.

Twenty-two consecutive obese patients were given very-low-calorie diet (VLCD) in the form of a casein and lactose preparation dissolved in orange juice containing 43.0 g protein, 30.4 g carbohydrate and 1.1 g lipid in a total of 317 kcal (1.3 MJ) daily. VLCD was given intermittently in eight-week periods alternating with three-week periods of conventional diet (900-1200 kcal, 3.8-5.0 MJ) to ensure recuperation of lean body mass and to establish a therapy which may facilitate indefinite patient compliance. In case of persisting hunger, diethyl-propion was given in small doses. The median observation time was nine weeks (range 1-37 weeks). The median weight loss was 15.5 kg (range 3.8-39.2 kg), and the median overweight decreased from 85.5 per cent (range 43-135 per cent) to 61.0 per cent (range 19-100 per cent). Blood glucose and cholesterol fell significantly (P < 0.01), and no major side-effects were observed.

Adolescent↗
PubMedDate not supplied

Does 1,25(OH)2D3 accelerate spinal bone loss? A controlled therapeutic trial in 70-year-old women.

The progress of spinal bone loss was monitored by measurements of the vertebral body height of T6 to L5 in seventy 70-year-old women who participated in a controlled, double-blind therapeutic trial. They were treated for one year by 1,25(OH)2D3, 0.50 micrograms a day (or less if hypercalcemia occurred) and cyclical estrogen/gestagen, alone or combined, or placebo. Sufficient calcium intake was ensured in all. The vertebral body height decreased significantly, by 1%, in both of the 1,25(OH)2D3 groups, whereas it remained unchanged in the hormone and the placebo + calcium group. This observation does not encourage the use of 1,25(OH)2D3 for prevention or treatment of postmenopausal bone loss.

Aged↗